FDA Cites Contaminated Loratadine Study In MDS Pharma Letter
This article was originally published in The Tan Sheet
Executive Summary
MDS Pharma Services' "inadequate" approach to investigating contamination in a loratadine bioequivalence study will place future data submissions from the firm under increased scrutiny from FDA, according to a recent letter to the company